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Beta-blockers are important agents in the treatment of cardiovascular diseases. They are used in hypertension, ischaemic heart disease, chronic systolic heart failure, hypertrophic cardiomyopathy, and arrhythmias, as well as in glaucoma. In chronic systolic heart failure they are very effective and reduce mortality by 35% in addition to the effects by antagonists of the renin-angiotensin-aldosterone system (RAAS) regardless of whether the aetiology is ischaemic heart disease or cardiomyopathy. With such wide applications, it has been important to find out the effects in situations where a heart disease might be a complication, i.e. in surgical situations in both cardiac and cardiac non-cardiac surgery. Further, could the beneficial effects of a beta-blocker in ischaemic heart disease be important if treatment is initiated prior to surgery in those patients who were untreated. Such questions have been addressed over the last 20 years and the answers have been misleading and confusing until recent years when the evidence seems to be more harmonized.
There have been many studies in patients with or at risk for ischaemic heart disease undergoing non-cardiac surgery, some underpowered 1 others with thousands of patients 2 using different beta-blockers and different protocols, i.e. with or without extensive risk assessment and with application of the beta-blocker immediately or several days before surgery. While some found protective effects of beta-blockers on myocardial infarction, others reported an increased mortality and stroke when the beta-blocker was given immediately before non-cardiac surgery, 3 as also reviewed by the Editors of the European Heart Journal, 4 suggesting that the dosing regimen and possibly the type of beta-blockers might at least in part play a role. As a result, the ESC guidelines for non-cardiac surgery have been modified and they now state 'Perioperative continuation of betablockers is recommended in patients currently receiving the medication' with recommendation IB. 5 In contrast, in patients off beta-blockers, pre-and perioperative use of the drugs is now recommended to be more restricted. Nevertheless,the perioperative use of beta-blockers in non-cardiac surgery continues and it is therefore of value to follow the safety of these drugs in the perioperative situation. In this issue of the journal, Jørgensen and co-workers report their investigation in a large cohort of Danish patients undergoing non-cardiac surgery regarding the safety of various beta-blockers. 6 In addition, as it is stated in the ESC guidelines 'Discrepancies in the effects of beta-blockers can be explained by differences in patient characteristics, type of surgery, and the methods of beta-blockade (timing of onset, duration, dose titration, and type of drug).', 5 they have analysed the data by type of beta-blocker and duration of therapy. They could use several national Danish registries where patients can be followed across these data sets by their unique identifier codes. The primary endpoint was 30-day all-cause mortality and they also assessed 30-day cardiovascular events by a composite of nonfatal myocardial infarction, non-fatal stroke, or cardiovascular death. During a 7-year period, 2005-2011, they included an impressive number of patients, 61 660, on beta-blockers undergoing non-cardiac surgery of whom 67.1% were receiving metoprolol and only 9.6, 9.0, and 7.4% were receiving atenolol, carvedilol, or propranolol, respectively. Primary and secondary endpoints did not significantly differ among the different beta-blockers except for patients with previous myocardial infarction who were at significantly lower risk of all-cause mortality when treated with carvedilol. Interaction analyses for all-cause mortality with the different beta-blockers showed no interaction by age, diabetes, surgery priority, duration of anaesthesia, or surgery risk, which is re-assuring. However, this type of analysis has to rely on complicated statistical adjustments as is reflected in their Table 1 . Indeed, all baseline characteristics differed significantly between the different beta-blocker groups. There are obvious reasons for the use of a beta-blocker in a certain patient with a certain diagnosis. When looking into the subgroup of patients with prior heart failure (Appendix carvedilol compared with 66.3% receiving metoprolol. However, the concomitant use of a RAAS antagonist was 76.7% in the carvedilol group compared with 54.7% in the metoprolol group. I assume this is because the use of carvedilol was selected because of a diagnsis of systolic heart failure. A limitation as pointed out by the authors is that metoprolol succinate and tartrate could not be examined individually due to identical ATC codes. In the follow-up of the COMET study, where carvedilol was superior to metoprolol tartrate in patients with systolic heart failure, criticism was raised that metoprolol tartrate was not documented in heart failure unlike metoprolol succinate used in the MERIT trial. 7 Based on later experience, we strongly believe that in systolic heart failure, it is the degree of heart rate reduction which is the most important factor. With a similar degree of heart rate reduction carvedilol is superior to metoprolol in terms of survival, but both agents are effective and it is important that one of the recommended beta-blockers is used.
In summary, in patients undergoing non-cardiac surgery, the use of different beta-blockers in subgroups of patients with heart failure, previous myocardial infarction, diabetes, or uncomplicated hypertension, the choice of a specific beta-blocker subtype does not seem to affect the risks of adverse events in patients. Accordingly, the choice of a specific beta-blocker based on a background diagnosis can be maintained and no adjustment is needed when non-cardiac surgery is to be performed. 
